AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

1. (Withdrawn) An antibody that is raised against and that recognizes an amino acid sequence that is present between the 180th and the 194th, or between the 237th and the 251st amino acid residues of SEQ ID NO: 1.

2. (Withdrawn) The antibody of claim 1, which is a monoclonal antibody.

3. (Canceled)

4. (Withdrawn) A pharmaceutical composition, which comprises the antibody of claim 1 or 2 as an active ingredient.

5. (Canceled)

6. (Withdrawn) The pharmaceutical composition of claim 4, which is effective against X-linked hypophosphatemic rickets.

7.-19. (Cancelled)

20. (Previously Presented) An antibody produced by a hybridoma whose accession number is FERM BP-7838, FERM BP-7839, FERM BP-7840, or FERM BP-8268.

21. (Previously Presented) A pharmaceutical composition, which comprises the antibody of claim 20 as an active ingredient.

22. (Currently Amended) ~~The~~ A pharmaceutical composition comprising an antibody produced by a hybridoma whose accession number is FERM BP-7838, FERM-7839 or FERM BP-8268, wherein the composition ~~of claim 21, which~~ is effective against at least one disease

selected from the group consisting of X-linked hypophosphatemic rickets, hypophosphatemia, and osteoporosis.

23. (Currently Amended) An antibody which is competitive with the antibody produced by a hybridoma whose accession number is FERM BP-7838, FERM BP-7839, ~~FERM BP-7840,~~ or FERM BP-8268 upon binding with the polypeptide consisting of the amino acid sequence represented by SEQ ID NO: 1 and which can neutralize the FGF-23 activity.

24. (Previously Presented) A pharmaceutical composition, which comprises the antibody of claim 23 as an active ingredient.

25. (Previously Presented) The pharmaceutical composition of claim 24, which is effective against at least one disease selected from the group consisting of X-linked hypophosphatemic rickets, hypophosphatemia, and osteoporosis.